Avitar announces successful completion of clinical trials of drugs of abuse tests for amphetamine and methamphetamine by its associate, Sun Biomedical Laboratories

Business Wire, March 6, 1997

CANTON, Mass.--(BUSINESS WIRE)--March 6, 1997--Avitar, Inc. ("the Company") [Nasdaq SmallCap Market:AVIT (Common Stock); AVITW (Redeemable Warrants)] today announced the successful completion of clinical trails of the Visualine II urine drugs of abuse tests for amphetamine and methamphetamine. These rapid point of care tests were compared to licensed laboratory tests at a major Eastern medical center. Discordant samples were resolved by the use of a generally accepted reference method (GC/MS), and in each case where the Visualine II test and the laboratory test disagreed, the Visualine II test was found to give the correct answer. The development of these two test will extend the line of drugs of abuse test available from Avitar and Sun Biomedical to seven tests. These two new tests will soon be submitted for regulatory review.

Dr. Carl Good III, who recently joined Avitar as Vice President of Research and Development, noted, "These very positive results have implications beyond urine testing. Avitar and Sun Biomedical Laboratories are currently in a joint program to develop saliva drugs of abuse tests that will be derived from the urine tests. In addition to the previously-announced progress in the saliva test development program, these two test will help broaden the opportunity for saliva test collection."

The Company designs, develops, manufactures and markets healthcare products and services including Hydrasorb(TM), a proprietary line of polyurethane wound care dressings. The Company also provides healthcare cost containment services to employers and third-party payors.

This press release contains forward looking statements which involve numerous risks and uncertainties. The Company's actual results could differ materially from those anticipated in such forward looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.

CONTACT: AVITAR, INC.

Peter Phildius, Chairman of the Board

(617) 575-9790

or

Jay Leatherman, Chief Financial Officer

(203) 265-3594